From the Journals

Dupilumab Faces Trial in Chronic Hives

Phase III CUPID-C trial evaluates biologic therapy in patients with chronic spontaneous urticaria uncontrolled by antihistamines.

Share

Dupilumab has shown promise in reducing itch severity and urticaria activity in patients with chronic spontaneous urticaria (CSU) who do not respond adequately to standard antihistamine treatment, according to the LIBERTY-CSU CUPID-C trial. The randomized trial involved 151 patients across nine countries and demonstrated a significant improvement in itch scores and overall disease activity after 24 weeks of treatment. The drug was well-tolerated, with adverse events similar to placebo, suggesting its potential as a safe option for CSU patients. Thomas B. Casale, MD, and colleagues concluded that dupilumab reinforces clinical benefits for patients with CSU who are refractory to histamine 1-receptor antagonists.

Original Source(s)

Dupilumab Faces Trial in Chronic Hives

  • by Kathryn Wighton

  • March 12, 2026

Related Content

HS Linked to Higher Self-Harm, Suicide Risk

Prior self-harm episodes and nonviolent methods are more common among HS patients who die by suicide, new research finds.

Dual-Frequency Radiofrequency for Facial Laxity?

Investigators report high 90-day response rates with no persistent adverse events.

Bimekizumab in Psoriasis: 3-Year Outcomes

Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.